第二代重组卡介苗菌株结合了对小鼠结核病的保护作用和免疫功能低下宿主中增强的安全性特征。
A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
机构信息
Australian Institute of Tropical Health and Medicine, James Cook University, Cairns & Townsville, QLD, Australia.
Centro de Investigación y Asistencia en Tecnología y diseño del Estado de Jalisco (CIATEJ), A.C., Biotecnología Medica y Farmacéutica, Guadalajara, Mexico.
出版信息
Vaccine. 2024 Oct 24;42(24):126291. doi: 10.1016/j.vaccine.2024.126291. Epub 2024 Sep 5.
Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). While BCG protects against TB in children, its protection against pulmonary TB in adults is suboptimal, and the development of a better TB vaccine is a global health priority. Previously, we reported two recombinant BCG strains effective against murine TB with low virulence and lung pathology in immunocompromised mice and guinea pigs. We have recently combined these two recombinant BCG strains into one novel vaccine candidate (BCGΔBCG1419c::ESAT6-PE25SS) and evaluated its immunogenicity, efficacy and safety profile in mice. This new vaccine candidate is non-inferior to BCG in protection against TB, presents reduced pro-inflammatory immune responses and displays an enhanced safety profile.
卡介苗（BCG）仍然是唯一获准用于预防结核病（TB）的疫苗。BCG 虽然可以预防儿童结核病，但对成人肺结核的保护效果并不理想，因此开发一种更好的结核病疫苗是全球卫生的重点。此前，我们曾报道过两种重组 BCG 菌株，它们在免疫功能低下的小鼠和豚鼠中具有针对鼠型结核的有效保护作用，同时还具有低毒力和肺部病理学特征。我们最近将这两种重组 BCG 菌株合并为一种新型候选疫苗（BCGΔBCG1419c::ESAT6-PE25SS），并在小鼠中评估了其免疫原性、疗效和安全性。与 BCG 相比，这种新的候选疫苗在预防结核病方面具有非劣效性，表现出较低的促炎免疫反应，并且具有更好的安全性。
Zotero 插件